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RESEARCH ARTICLE Open Access
Switching iron sucrose to ferric
carboxymaltose associates to better control
of iron status in hemodialysis patients
Jesse M. G. Hofman1,6* , Michele F. Eisenga1, Adry Diepenbroek1, Ilja M. Nolte2, Bastiaan van Dam3,
Ralf Westerhuis4, Stephan J. L. Bakker1, Casper F. M. Franssen1 and Carlo A. J. M. Gaillard5
Abstract
Background: Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in
hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has
not yet been performed in HD patients.
Methods: We performed a retrospective audit on records of 221 stable HD patients from different HD centers in the
Netherlands, who were switched from IS to FCM on a 1:1 ratio. To assess the effect of the switch on iron
status parameters, data from 3 time points before and 3 time points after the switch were analyzed using
linear mixed effects models. Subanalyses were done in 2 subgroups of patients anemic or iron deficient at
baseline.
Results: Hemoglobin increased in all groups (anemic [1.4 g/dL, P < 0.001] iron deficient [0.6 g/dL, P < 0.001]),
while the weekly iron dose was significantly lower when patients received FCM compared to IS (48 vs 55 mg/week, P =
0.04). Furthermore, serum ferritin and transferrin saturation increased in all groups (anemic [64 μg/L, 5.0%, P < 0.001]
iron deficient [76 μg/L, 3.6%, P < 0.001]). Finally, the darbepoetin α dose decreased significantly in all groups
(anemic [− 16 μg/wk., P = 0.01] iron deficient [− 11 μg/wk., P < 0.001]).
Conclusions: In this real-life study in HD patients, a switch from IS to FCM resulted in an improvement of iron
status parameters despite a lower weekly dose of FCM. Furthermore, the ESA dose was reduced during FCM,
while hemoglobin levels increased.
Keywords: Ferric carboxymaltose, Iron sucrose, Hemodialysis, Iron status, ESA
Background
Anemia is a frequent complication of chronic kidney
disease (CKD) [1]. In CKD, the main causes of anemia
are deficiency of erythropoietin, iron-restricted erythro-
poiesis and anemia of the chronic disease (ACD) [2–4].
The latter originates from the chronic inflammation that
is a hallmark of CKD patients and has been shown to be
associated with adverse outcomes such as cardiovascular
events, end-stage renal disease, increased mortality, and
decreased quality of life [5]. In ACD, pro-inflammatory
cytokines upregulate hepcidin production in the liver
which subsequently hampers iron uptake from the gut
and iron release from the reticulo-endothelial system [6,
7] which leads to functional iron deficiency that nega-
tively affects erythropoiesis. Furthermore, increased iron
utilization due to the use of erythropoiesis stimulating
agents (ESA), and iron loss as a result of dialysis-related
blood loss contribute to the high prevalence of anemia
in patients with CKD [8].
Oral administration of iron has limited efficaciousness
and is associated with gastrointestinal side effects. By
means of intravenous iron, gastrointestinal absorption is
bypassed and incorporated more rapidly [5]. Indeed, it
has been established that intravenous iron supplementa-
tion as a treatment for iron deficiency anemia is superior
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to oral iron supplementation in non-dialysis dependent
CKD, hemodialysis (HD) and peritoneal dialysis patients
[9–11]. Furthermore, ESA requirements have been
shown to be decreased in patients receiving intravenous
iron [12].
Nowadays, several intravenous iron supplementations
are available, of which iron sucrose (IS) and a more re-
cently introduced intravenous (IV) iron compound, fer-
ric carboxymaltose (FCM) (brand names Venofer and
Ferinject, respectively) are frequently used. Although the
efficacy of IS and that of FCM for treatment of anemia
in CKD patients have been studied individually by com-
paring the formulations to oral iron supplementation
[10, 13], a head to head comparison of these two intra-
venous formulations has never been performed in HD
patients. Therefore, the goal of this audit is to analyze
the effects of a switch from IS to equally dosed FCM.
Hence, we performed an audit on records of HD pa-




We conducted an audit using data retrospectively gath-
ered from HD patients who were switched from IS to
FCM because of a change in hospital policies. Patients
from four dialysis centers were included (Dialysis Center
Groningen, n = 110, University Medical Center Gro-
ningen, n = 11, Dialysis Center “Noord-West Zieken-
huizgroep”, n = 54, and Dialysis Center Amersfoort, n =
46). We analyzed a study period of 15 months in total,
during which we studied 6 time points, each 3 months
apart, as illustrated in Fig. 1. During the 6 months
pre-switch patients received IS, and during the 9 months
post switch they received FCM. During both periods,
blood was sampled every 3 months as part of the clinical
routine, at least one week after administration of IV
iron. The baseline time point was one of the three time
points before the switch, and was defined for each pa-
tient separately when the patient had at that time point
been using maintenance IV iron medication for ≥6 months,
and the patient had been on HD treatment for at least
3 months. The need for participant consent was waived by
the medical ethical committee in the UMCG for the act
on Medical Research Involving Human Subjects (in
Dutch:WMO).
Study population
The study population consisted of CKD patients who
were at least 18 years old, were on uninterrupted HD
treatment for a period of at least 3 months before the
switch and 3 months after the switch, were using IS at
the start of the investigational period, and were subse-
quently switched from IS to FCM. Patients with any ma-
lignancy diagnosed in the five years prior to the
investigational period were excluded. In all three cohorts
anemia was diagnosed when hemoglobin was < 12 g/dL.
Subsequently a diagnostic workup was performed to rule
out causes of anemia besides CKD, like bleeding or ac-
tive infection. If these were ruled out, IV iron therapy
was initiated when there was an absolute iron defi-
ciency (transferrin saturation (TSAT) < 20% and ferritin
< 100 ng/mL) or when TSAT was ≤20%, or ferritin was
≤200 μg/l, and an increase in hemoglobin concentration
was desired without increasing the ESA dose. In this
case, the patient received 100 mg of iron per week for
10 weeks. Subsequently, iron medication was ceased,
and after 4 weeks the patient’s iron stores were assessed
by the treating nephrologist, who decided on the
treatment plan. If ferritin was < 200 μg/l, or TSAT was
< 20%, IV iron was initiated at a dose of 100 mg per
week. If ferritin was 200–500 μg/l, and/or TSAT was
20–30%, the dose was 100 mg every two weeks. If ferritin
was 500–800 μg/l and/or TSAT was 30–50%, the dose
was 100 mg every four weeks. If ferritin was > 800 μg/l
and/or TSAT was > 50%, no IV iron was administered. If
IV iron alone was not sufficient to improve hemoglobin
levels, the treating nephrologist added an ESA to the
therapeutic regime. In all cases, the patient was


















































Fig. 1 Graphical representation of the time points used for data collection from patient records. The figure shows the amount of patients included at
each timepoint, the percentage of people included in the anemic (Hemoglobin < 10 g/dL) and iron deficient (TSAT < 20% and Ferritin < 300 μg/L)
subgroups, and the median (IQR) iron dose (mg/week) at each timepoint. Idef, iron deficient
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last administration of IV iron. The goal of this treatment
was to prevent hemoglobin from dropping below 10 g/dL,
while not routinely exceeding 12 g/dL. Iron was always
administered in the final 30 min of the HD session. The
protocol did not change after switching from IS to FCM.
This is in accordance with the 2015 Dutch National feder-
ation for Nephrology guidelines for management of
anemia in kidney disease that are based on the most re-
cent KDIGO guidelines and the ERBP position statement
on the KDIGO guidelines [14].
After application of the exclusion criteria, data from
221 of the original 280 patients who were switched from
IS to FCM were included in the final analyses. Following
inclusion of data from the baseline time point, data was
included for analysis up until the final time point
9 months after the switch, or until follow-up was cen-
sored because the patient died, stopped using FCM, or
stopped HD treatment due to any cause. As depicted in
Fig. 1, at T-6 data from 155 patients were included, at
T-3 data from 178 patients were included, and at T-1, by
definition, data from all 221 patients were included.
After inclusion, all patients were followed up until T3,
the first time point, i.e. 3 months after the switch, 194
patients were followed up until T6, i.e. 6 months after
the switch, and 162 until T9, i.e. 9 months after the
switch. As a result, we analyzed the data with linear
mixed models, which is considered to be robust to miss-
ing values and is therefore able to deal with missing data
at certain time points. We also assessed the effect of the
factor “time” on the period from T-6 to T-1 (patients on
IS) and T3 to T9 (patients on FCM).
Audit
The primary objective of this analysis was to deter-
mine whether the switch from IS to FCM modulated
iron status parameters in relation to iron dose and
ESA dose. We used the parameters TSAT and serum
ferritin over time to quantify the effect on both abso-
lute and functional iron deficiency, as they have been
shown to be key parameters in the diagnosis of iron
deficiency anemia (IDA) [15], and hemoglobin over
time to determine the effect on the severity of
anemia. To further address other effects of the switch
on erythropoiesis, iron metabolism and inflammation,
we included ESA dose, iron dose, serum iron, mean
corpuscular volume (MCV), hematocrit, reticulocyte
count, total iron-binding capacity and C-reactive pro-
tein (CRP) as secondary objectives. All data was gath-
ered from blood samples that were analyzed at the
main laboratory in each hospital.
Statistical analysis
Normally distributed variables are described as mean ±
standard deviation (SD), and skewed variables as median
and interquartile range (IQR). Categorical variables
are expressed as percentage. Linear mixed effects
models, which are within-person analyses, were used
to assess the effect of the medication switch on iron
status and dialysis parameters. Random effects were
patient identification number (ID) and an interaction
between ID and switch. The most appropriate covari-
ance structure was determined for each outcome vari-
able separately. Fixed effects were switch, factor time
classified as three options for the three time moments
before and after switch, time2 to account for the pos-
sible nonlinear relation between time and the out-
come variable, iron deficiency at baseline, anemia at
baseline, and interactions between switch and anemia,
switch and iron deficiency, switch and time, and
switch and time2. The least significant fixed effects
were removed in a stepwise manner for each variable,
until only effects with a significance of < 0.1 were left
in order to achieve a good model fit. Subsequently,
the estimated marginal means of parameters before
and after the switch were compared to determine the
main effect of the switch. Skewed variables were ln-
transformed in order to achieve a normal distribution.
Subanalyses were performed in a subgroup of iron de-
ficient patients, characterized by TSAT < 20% and fer-
ritin < 300 μg/L (n = 55), and anemic patients,
characterized by a hemoglobin of < 10 g/dL in men
and women [16], which was the lower end of the
hemoglobin target range of 10–12 g/dL (n = 24). Data
analysis was performed in SPSS statistics version 22.0
(IBM Corporation, Chicago, IL, USA).
Results
We included 221 HD patients (mean age 65 ±
15 years), of whom 24 were anemic at baseline, and
55 iron deficient at baseline. The prevalence of hyper-
tension and diabetes mellitus was 58.6% and 31.8%,
respectively. There was no significant correlation be-
tween ferritin and CRP at baseline in the entire group
(β − 0.090, P = 0.33), the anemic group (β 0.286, P =
0.32), or the iron deficient group (β − 0.128, P = 0.64).
Additional baseline characteristics of the entire group,
as well as anemic and iron deficient subgroups are
shown in Table 1.
Effects of the switch in the entire cohort
The models used to analyze the effect of the switch
on each parameter are described in Additional file 1:
Table S1. The main effects of the switch from IS to
FCM on all parameters are reported in Table 2. The
dosage of iron medication decreased significantly after
switch from IS to FCM (− 7 mg/wk., P = 0.04), while
hemoglobin (0.64 g/dL, P < 0.001) and hematocrit
(0.02, P < 0.001) increased significantly. Furthermore,
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after the switch from IS to FCM, serum ferritin in-
creased significantly (64 μg/L, P < 0.001) as well as
TSAT (3.4%, P < 0.001) (Fig. 2). The proportion of re-
ticulocytes in the blood and serum transferrin de-
creased significantly (− 0.1 g/L, P = 0.002). The factor
time was not a significant predictor of TSAT and
serum ferritin both before and after the switch; hence
the data shown below are fully the result of the
switch. The ESA dose was decreased significantly in
patients using darbepoetin α, but not in those using
epoetin β. MCV showed a slight significant increase.
Other parameters did not change significantly as re-
sult of the switch of IS to FCM.
Effects of the switch in anemic patients alone
When assessing the same parameters in specifically
anemic patients at baseline, hemoglobin (1.4, P < 0.001),
hematocrit (0.04 P < 0.001), TSAT (5.0%, P < 0.001), and
serum iron (1.9 μmol/L, P = 0.008) seemed to increase
more as a result of the switch in this subgroup com-
pared to the entire population, while the darbepoetin α
dose decreased more (− 16 μg/wk., P = 0.010), as shown
in Table 2. The models show that having a hemoglobin
level of < 10 g/dL at baseline enhances the effect of the
switch beyond the effect the switch has in non-anemic
individuals on hemoglobin, hematocrit, TSAT, serum
iron, and ESA dose. For the other variables, including
Table 1 Baseline characteristics of patients included in the study
All patients n = 221 Anemic n = 24 Iron deficient n = 55
Sex (% male) 62.3 45.5 67.3
Age (years) 65 ± 15 62 ± 16 64 ± 18
Diabetes mellitus (%) 31.8 35.0 20.8
Hypertension (%) 58.6 65.0 54.2
BMI (kg/m2) 24.7 ± 4.1 25.4 ± 4.5 25.0 ± 3.7
Systolic BP pre-HD (mmHg) 140 ± 24 135 ± 26 141 ± 21
Diastolic BP pre-HD (mmHg) 69 ± 14 70 ± 15 69 ± 13
Residual diuresis (%) 47.6 37.5 42.9
Ultrafiltration (L) 2.15 ± 0.96 2.55 ± 0.76 1.98 ± 0.92
Dialysis vintage (months) 22 (11–49) 22 (10–44) 26 (9–55)
Urea pre-HD (mg/dL) 23.2 ± 7.2 21.8 ± 7.8 24.5 ± 6.9
Creatinine pre-HD (μg/dL) 808 ± 250 842 ± 257 870 ± 259
Hb (g/dL) 11.7 ± 1.2 9.4 ± 0.5 11.8 ± 1.3
Ht 0.35 ± 0.03 0.30 ± 0.02 0.36 ± 0.04
Reticulocytes (%) 13.7 (10.3–19.0) 14.0 (12.0–22.3) 14.0 (12.0–18.0)
MCV (fL) 95.4 ± 6.4 96.8 ± 6.9 91.0 ± 5.6
Ferritin (μg/L) 416 (227–625) 514 (297–700) 176 (116–226)
Transferrin (g/L) 1.9 ± 0.3 1.9 ± 0.4 2.1 ± 0.3
TSAT (%) 20.8 (15.0–26.5) 18.5 (14.0–31.3) 14.0 (12.0–16.0)
Serum iron (μg/L) 9.3 (7.0–12.8) 9.0 (7.0–14.0) 7.0 (6.0–8.0)
TIBC (μmol/L) 46.0 ± 9.2 44.3 ± 9.0 49.4 ± 9.6
Iron medication (mg/wk) 50 (25–100) 100 (50–100) 50 (33–100)
Darbepoetin α (μg/wk) 30 (10–50) 40 (50–60) 30 (16–60)
Epoetin β (IE/wk) 8000 (4000–12,000) 8000 (7000–13,500) 8000 (4000–12,000)
CRP (mg/L)a 6.2 (2.0–16.0) 13.5 (2.0–40.0) 15.0 (1.5–56.0)
Phosphate (mmol/L) 1.59 (1.29–1.93) 1.73 (1.31–2.16) 1.61 (1.3–2.0)
Potassium (mmol/L) 4.9 (4.5–5.4) 4.8 (4.5–5.6) 5.0 (4.6–5.5)
Sodium (mEq/L) 138.0 ± 3.1 138.7 ± 2.8 137.3 ± 3.3
Normally distributed variables are described as mean ± SD and variables with a skewed distribution as median, IQR. Dialysis duration and frequency are described
as mode
BP, blood pressure; HD, hemodialysis; Hb, hemoglobin; Ht, hematocrit; MCV, mean corpuscular volume; TSAT, transferrin saturation; TIBC, total iron binding
capacity; CRP, C-reactive protein
aData available in 119 HD patients before the switch
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ferritin (Fig. 2), results were similar to those described
for the entire population.
Effects of the switch in iron deficient patients alone
In this subgroup, the ESA dose decreased more than in
the entire population (darbepoetin α: − 11 μg/wk., P <
0.001) (Table 2). Furthermore, it shows that being iron
deficient at baseline enhances the effect of the switch on
serum ferritin (76 μg/l, P < 0.001). For all the other vari-
ables the results were similar to those described for the
entire population.
Discussion
In this analysis, we have shown that the switch from IS
to FCM in HD patients was associated with a signifi-
cant improvement of iron status, unrelated to iron
dose. After the switch to FCM hemoglobin, hematocrit,
serum ferritin, TSAT, and MCV increased, while trans-
ferrin levels decreased, reflecting erythropoiesis which
is less restricted by iron deficiency [17]. Furthermore,
ESA dose decreased after the switch to FCM. This is, to
our knowledge, the first investigation to compare the
effects on iron status of a switch to FCM from IS in
dialysis-dependent CKD patients.
In the subgroup of anemic patients at baseline espe-
cially, the effect of the switch on iron status was even
more pronounced, despite the fact that these patients
were prescribed significantly less iron and a smaller ESA
dose after the switch. Switching from IS to FCM resulted
in a marked increase in TSAT in both groups, a large in-
crease of MCV in the anemic group, and an increase in
serum ferritin in both groups. Although the baseline
hemoglobin and iron status in the anemic and iron defi-
cient groups were worse, the large improvement of iron
Table 2 Main effect of medication switch in the total population and subgroups
Total population (n = 221) Anemic at baseline (n = 24) Iron deficient at baseline (n = 55)
Before (SE) After (SE) P Before (SE) After (SE) P Before (SE) After (SE) P
Ln Irondose (mg/wk) 4.007 (0.063) 3.880 (0.063) 0.04 4.114 (0.046) 3.987 (0.045) 0.006 4.094 (0.086) 3.967 (0.086) 0.11
Irondose (mg/wk) 55 48 61 54 60 53
Ln Darbepoetin α (μg/wk) 3.528 (0.122) 3.299 (0.121) 0.001 3.809 (0.230) 3.375 (0.227) 0.01 3.649 (0.155) 3.290 (0.155) < 0.001
Darbepoetin α (μg/wk) 34 27 45 29 38 27
Ln Epoetin β (IE/wk) 9.038 (0.099) 8.911 (0.096) 0.06 N/Aa N/Aa N/Aa N/Aa N/Aa N/Aa
Epoetin β (IE/wk) 8400 7400 N/Aa N/Aa N/Aa N/Aa
Hb (g/dL) 11.00 (0.11) 11.64 (0.10) < 0.001 10.10(0.196) 11.50 (0.184) < 0.001 11.21 (0.134) 11.85 (0.130) < 0.001
Ht 0.338 (0.003) 0.358 (0.003) < 0.001 0.316 (0.006) 0.358 (0.006) < 0.001 0.345 (0.004) 0.364 (0.004) < 0.001
MCV (fL) 94.10 (0.453) 94.92 (0.452) 0.001 94.10 (0.453) 94.92 (0.452) 0.001 91.46 (0.759) 92.28 (0.758) 0.08
Ln Reticulocytes (%) 2.613 (0.036) 2.704 (0.033) < 0.001 2.613 (0.036) 2.704 (0.033) 0.002 2.613 (0.036) 2.704 (0.033) 0.004
Reticulocytes (%) 13.6 14.9 13.6 14.9 13.6 14.9
Ln Ferritin (μg/L) 5.659 (0.041) 5.860 (0.055) < 0.001 5.659 (0.041) 5.860 (0.055) < 0.001 5.132 (0.071) 5.503 (0.095) < 0.001
Ferritin (μg/L) 287 351 287 351 169 245
Ln Transferrin (g/L) 0.640 (0.013) 0.611 (0.014) 0.002 0.640 (0.013) 0.611 (0.014) 0.04 0.702 (0.022) 0.674 (0.023) 0.03
Transferrin (g/L) 1.9 1.8 1.9 1.8 2.0 2.0
Ln TSAT (%) 2.841 (0.037) 3.019 (0.044) < 0.001 2.760 (0.067) 3.035 (0.080) < 0.001 2.609 (0.050) 2.844 (0.062) < 0.001
TSAT (%) 17.1 20.5 15.8 20.8 13.6 17.2
TIBC (μmol/L) 47.648 (0.707) 47.225 (0.764) 0.35 47.648 (0.707) 47.225 (0.764) 0.12 50.240 (1.112) 49.818 (1.148) 0.53
Ln Serumiron (μmol/L) 2.13 (0.04) 2.26 (0.04) 0.003 2.08 (0.07) 2.29 (0.08) 0.008 1.96 (0.05) 2.14 (0.06) 0.001
Serumiron (μmol/L) 8.4 9.6 8.0 9.9 7.1 8.5
Ln CRP (mg/L) 1.999 1.825 (0.092) 0.23 1.999 (0.121) 1.825 (0.092) 0.004 1.999 (0.121) 1.825 (0.092) 0.20
CRP 7.4 6.2 7.4 6.2 7.4 6.2
Ultrafiltration (L) 2.307 (0.103) 2.214 (0.100) 0.23 2.459 (0.193) 2.235 (0.186) 0.22 2.307 (0.103) 2.214 (0.100) 0.32
Ln Phosphate 0.440 (0.020) 0.416 (0.020) 0.19 0.440 (0.020) 0.416 (0.020) 0.14 0.440 (0.020) 0.416 (0.020) 0.17
Phosphate 1.55 1.52 1.55 1.52 1.55 1.52
Shown in this table are the marginal estimated means of all data before and after the switch, as calculated with our model. Data is described as mean (SE).
P-values of paired samples t-tests are shown. Ln-transformed variables were transformed back in order to give insight into the effect size
SE, standard error; Hb, hemoglobin; Ht, hematocrit; MCV, mean corpuscular volume; TSAT, transferrin saturation; TIBC, total iron binding capacity; CRP,
C-reactive protein
aSample size was too small to draw useful conclusions
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status in these groups seems attributable to the effect of
switching from IS to FCM since we did not identify a
statistically significant general trend based solitarily on
the factor time.
These results seem to indicate that switching from IS
to similarly dosed FCM causes an increase in ferritin
and TSAT in all groups, which is more pronounced in
anemic patients. When speculating on possible mecha-
nisms why FCM seems to be more effective than IS in
replenishing iron stores, one could put forth the argu-
ment that FCM has increased bioavailability of elemental
iron compared to IS. FCM and IS are both composed of
an iron(III)-hydroxide core, surrounded by a carbohy-
drate shell (carboxymaltose and sucrose, respectively)
[18]. FCM has a higher molecular weight than IS
(150,000 v 43,300 Da) and a longer half-life (7–12 v 5–
6 h) which increase the area under the curve, indicating
that the bioavailability of FCM is greater than that of IS
[18]. A second explanation might be that FCM is much
more stable than IS, which prevents release of labile iron
into the blood, where it can saturate transferrin and lead
to significant amounts of non-transferrin bound iron
(NTBI) [19]. This causes not only a less efficient uptake
of iron by reticuloendothelial macrophages [18], but the
NTBI may also lead to oxidative stress [20]. At this point
it should be noted that there is no long-term data avail-
able on the pharmacokinetics of both compounds; there-
fore a direct comparison between the two compounds
Fig. 2 Bar charts showing the median serum ferritin and TSAT levels of the three time points before and after the switch for the entire population and
the 2 subgroups. Data is described as median and interquartile range
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cannot be performed. A head to head pharmacokinetic
study would be required before conclusions can be
drawn.
These results are in accordance with the results of the
REPAIR-IDA trial, a randomized controlled trial com-
paring FCM to IS in a group of 2584 non-renal IDA pa-
tients. Onken et al. describe a significant increase in
serum ferritin and TSAT in favor of FCM, 56 days after
drug administration [21]. We have demonstrated that
over a period of 9 months, a significant difference in
serum ferritin and TSAT continues to exist due to ad-
ministration of FCM.
One of the adverse effects of FCM described is hypo-
phosphatemia. We observed a nonsignificant 0.03 mmol/L
decrease in serum phosphate levels; hence, hypophospha-
temia did not become more prevalent as a result of the
switch from IS to FCM. This is in accordance with a clin-
ical trial in inflammatory bowel disease patients, which de-
scribed a transient decrease of serum phosphate levels in
the FCM group which resolved between week 4 and week
12 after the switch [22]. Our results contradict the find-
ings of a study by Hardy et al. specifically assessing the ef-
fect of FCM on serum phosphate levels compared to IS in
iron deficiency anemia patients. The authors found that
FCM caused significantly more hypophosphatemia than
IS, which resolved after a mean duration of 6 months [23].
It should be noted, however, that the latter study did not
comprise solitarily chronic kidney disease patients. Hence,
the diminished renal function and as such the lower risk
of developing hypophosphatemia in our study might have
resulted in a substantive difference between our identified
prevalence and the results as described by Hardy and
colleagues.
It is known, at least theoretically, that administration
of intravenous iron in CKD patients on the long term
might lead to an iron overload, which may produce
endothelial dysfunction, cardiovascular disease, and im-
mune dysfunction [24]. It seems plausible, based on our
results, that we can correct iron status parameters more
efficiently with FCM, at a lower dose, and as such a pu-
tative iron overload can be prevented. Furthermore, we
can also speculate that FCM administration could be
more cost-efficient than IS due to the lower iron and
ESA dose, which may lead to financial savings in the
long term [25]. A well performed cost-benefit analysis is
needed to substantiate this possible advantage of using
FCM as compared to IS.
A strength of our investigation is that it comprises a
comparison of multiple data points within one patient,
meaning that our results correspond better to a real-life
situation where a patient is switched from IS to FCM.
Moreover, it should be kept in mind that we censored
patients who stopped using FCM as data was no longer
available, likely contributing to the underestimation of
the effect of FCM as these patients will likely have iron
status parameters longer in target.
A limitation of our study is the longitudinal study de-
sign without randomization, making it difficult to draw
firm conclusions. A head-to-head comparison between
IS and FCM is needed to confirm our results. Further-
more, we acknowledge as limitation that we did not
assess the tolerability or safety of either IV iron prepar-
ation even though these factors play an important role
when prescribing. Although the safety of FCM has never
been compared to IS in the HD population specifically,
it has been assessed in other patient groups such as
non-dialysis dependent CKD in the REPAIR-IDA trial
[21]. In this trial, Onken et al. found no significant dif-
ference in the number of patients that reached a primary
composite safety endpoint. Hypertensive events immedi-
ately following drug administration occurred signifi-
cantly more in the FCM group than in the IS group,
with 7.45% of patients compared to 4.36% experiencing
an event, however, hypertensive events occurred on
non-dosing days nearly twice as often in the IS group.
Conclusions
In conclusion, the switch from IS to FCM was accompan-
ied by a marked improvement in iron status parameters,
despite a lower iron dose. In addition, use of FCM resulted
in an increase in hemoglobin levels while ESA dose was
decreased. Our results need to be confirmed and delin-
eated in more detail in larger prospective studies.
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